BTG Plc reported its third consecutive year of profits for the year ended 31 March 2008, and forecast continued earnings growth during the current year. The UK life science company expects to see an increase in royalties from marketed products, while at the same time advancing its own products through development. On 31 March, the company had cash and cash equivalents of £57 million compared with £43 million a year earlier.
